Osteoporosis Condition Center Debuts

Published Online: Thursday, June 14, 2012
Follow Pharmacy_Times:

This month, we introduce a new condition center on www .PharmacyTimes.com covering osteoporosis. The condition affects approximately 1 of 5 women in the United States, and occurs when a patient’s body produces new bone more slowly than it removes old bone. As a result, falls and simple actions are more likely to result in fractures, particularly in the wrist, hip, and spine.

The condition affects men and women of all races, but women are more likely to have it. Additional risk factors include having a small body frame, family history, lowered sex hormone levels, low calcium intake, thyroid problems, consistent use of corticosteroid medications, and eating disorders. Treatment options include intravenous, nasal, and oral medications, and lifestyle changes. Pharmacists can play an important role in emphasizing the importance of medication adherence as well as preventive measures.

Some of the topics covered in the osteoporosis condition center include:

  • Indications that bisphosphonates used to prevent osteoporosis may increase the risk of fracture
  • The relationship between early menopause and increased risk of osteoporosis
  • Genetic variations associated with osteoporosis risk


Related Articles
The media has been quick to discuss research findings on vitamin D supplementation’s potential role in combating osteoporosis, correcting deficiency in chronic kidney disease, improving heart health, and extending life, which raises the question of whether patients should be screened routinely for vitamin D deficiency.
Well-trained pharmacy technicians can free up pharmacists’ time for osteoporosis management services by identifying patients who do not require pharmacist intervention.
Current risk assessment strategies for reducing fractures related to osteoporosis among women fail to accurately predict who will experience major osteoporotic injuries.
New guidelines from the American Thyroid Association recommend that levothyroxine should remain the standard of care for treating hypothyroidism.
Latest Issues
$auto_registration$